| abstract |
The present invention relates to the use of biscarbonyl oleanolic acid for preparing a drug for preventing and treating viral hepatitis B. The application of medicine in hepatitis virus infection disease. The compound has a significant inhibitory activity of HBsAg and HBeAg secreted by HepG2.2.15 cells. At the concentration of 100 μg/ml on the 8th day, it inhibits the secretion of HBsAg and HBeAg by 60.1% and 60.9%, respectively. At this concentration, it inhibits HBV ‑DNA replication even showed an inhibition rate of over 94%. The above shows that the dicarbonyl oleanolic acid can be expected to be used for the preparation of non-nucleoside drugs for the treatment of hepatitis B virus infection. The use of the inhibitor, and the preparation method thereof has simple steps, low cost, wide source of raw materials, and is easy to carry out industrial production. |